Gross revenue grew to R$2.9 billion in 3Q25, with Diagnostics up 12% and Hospitals and Oncology NE up 7% year-over-year. EBITDA margin improved to 26.5%, and leverage dropped to 2.38x, reflecting strong operational efficiency and capital structure improvements.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.